Scientifically reviewed by
Dr. Ky H. Le, MD
The information presented in this article is for educational and research purposes only, intended for laboratory professionals, researchers and collaborators. This content does not constitute medical or clinical advice.
Table of Contents
Vesilute is a two-amino-acid compound — glutamic acid and aspartic acid, sequenced as Glu-Asp — classified within the Khavinson family of short-chain peptide bioregulators.
Despite its minimal structure, vesilute peptide research suggests it may interact with gene expression machinery in urogenital tissues, placing it among the more structurally targeted compounds in the cytomedine class.
Highlights
- Vesilute (Glu-Asp) is a dipeptide bioregulator developed by Prof. Vladimir Khavinson, studied for proposed effects on urogenital tissue at the cellular level
- Research suggests the Glu-Asp sequence may interact with chromatin structures in urogenital cells, with proposed effects on gene expression and protein synthesis
- Animal and clinical research has examined vesilute’s effects on bladder smooth muscle contractility and urogenital tissue function in study models
- Vesilute is intended strictly for in vitro and laboratory research use; it is not approved for human administration
What Is Vesilute?
Vesilute belongs to the class of peptide bioregulators known as cytomedines — compounds developed over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology under Prof. Vladimir Khavinson.
Like other compounds in this class, vesilute is a short synthetic dipeptide modeled on peptide sequences identified in specific organ tissue. The Glu-Asp sequence (also noted as ED in single-letter amino acid code) appears across multiple tissue compartments, with research attention concentrated on the urogenital system.
Vesilute is also identifiable by the names glutamyl-aspartate or Vesilut, carrying the molecular formula C₉H₁₄N₂O₇ and a molecular weight of approximately 246 Da.
Related Product: Buy Vesilute peptide for laboratory research use.
The Khavinson Bioregulator Research Framework
Vesilute sits within a broader research model built across more than 40 years of investigation into short regulatory peptides.
Khavinson’s framework proposes that di-, tri-, and tetrapeptides — structurally based on sequences from specific organ tissues — display preferential regulatory activity within those same tissue types. Research published in Biogerontologydocumented that long-term study with certain peptide preparations was associated with measurable shifts in aging biomarkers and tissue function in rodent models, with some compounds correlated with lifespan extensions of 20–40% in experimental conditions.[1]
A 2025 review in Current Aging Sciencesummarized the framework’s central proposition: that short peptides regulate gene expression and protein synthesis at the cellular level, with tissue-specific effects tied to their amino acid composition.[2]
Researchers new to this compound class can find background context in the site’s overview of what distinguishes bioregulators from standard research peptides.
Proposed Cellular Mechanisms in Vesilute Peptide Research
Research into Glu-Asp and closely related cytomedines has focused on several distinct molecular pathways. The evidence base draws primarily from in vitro cell studies, animal models, and a smaller body of clinical observational research.
Gene Expression and Chromatin Interaction
A central hypothesis in Khavinson peptide research is that short sequences like Glu-Asp interact directly with specific DNA motifs — including the ATTT tetranucleotide (one adenine, three thymines) — modulating chromatin architecture in the cell nucleus.
The proposed effect is chromatin decondensation, which may reactivate silenced genes in aging or dysfunctional cells. Research on related cytomedine dipeptides suggests this mechanism may restore protein synthesis capacity where gene expression activity has declined with cellular age.[3]
Related research has also examines how bioregulatory peptides of this class may influence nucleolus organizer regions (NORs) — chromosomal sites governing ribosome assembly. Elevated NOR activity in study models has been linked to increased protein synthesis output, a finding with relevance to aging cell biology research.
A 2022 study in IJMSdemonstrated that five Khavinson-class peptides modulated key proliferative signaling patterns in the THP-1 monocytic cell line in vitro, including inhibition of pro-inflammatory cytokine expression — supporting the broader gene-regulatory model across multiple peptide types in this class.[4]
Smooth Muscle Signaling in Bladder Tissue Models
A second mechanistic focus in vesilute peptide research involves smooth muscle regulation in the urinary bladder.
The proposed pathway centers on inhibition of glycogen aggregation in bladder smooth muscle cells. By attenuating calcium signaling activity and associated energy expenditure, the Glu-Asp sequence is hypothesized to exert a relaxation-type effect on detrusor muscle tone in experimental models.
Separately, glutamate as a free amino acid has been shown to modulate smooth muscle contractility in urogenital tissues through ionotropic receptor activation — documented in an organ bath study of isolated human ureter tissue. This provides relevant cellular signaling context for the environment in which the Glu-Asp dipeptide operates.[5]
Microcirculation Observations in Study Models
A third area of interest — observed across multiple cytomedine compounds including vesilute — involves vascular smooth muscle tone and microcirculatory dynamics.
Inhibition of vascular glycogen aggregation is hypothesized to support vessel relaxation, reducing peripheral resistance in target organ tissues. Research into prostate tissue models has framed this as a secondary effect of cytomedine exposure in prostatic microvascular beds, with associated reductions in cell proliferation observed in preclinical models. Related research into the Chitomur bladder bioregulator has examined similar smooth muscle and tissue-remodeling pathways in urogenital research contexts.
Research in Animal and Clinical Models
Animal and clinical research provides a more applied layer to the mechanistic hypotheses above. These studies examine vesilute’s observed effects in living system models, with findings reported in the Khavinson bioregulator literature.
Detrusor Contractility
Experimental studies in rat models of infravesical obstruction examined vesilute’s effects on bladder smooth muscle behavior.[6]
Administration of the Glu-Asp compound in these models was associated with normalization of detrusor contractility parameters — the mechanical properties governing how bladder smooth muscle generates and sustains contraction. This line of animal research supports the smooth muscle signaling hypothesis and informs continuing in vitro work in urogenital tissue physiology.
Overactive Bladder Models
A prospective study involving 20 women with overactive bladder syndrome recorded changes in voiding frequency and urinary urgency following vesilute exposure.[6]
The study documented a reduction in daytime urination frequency from approximately 14 to 11 episodes daily, a decrease in urgency incontinence episodes, and reduced nocturia. These findings are interpreted in the context of the compound’s proposed neuromodulatory activity — specifically, its study as a potential co-mediator at neural junctions governing micturition.
Research into cytomedine exposure in prostatic tissue research models has recorded parallel changes in spermatogenic parameters in study populations, reflecting the organotropic breadth of this dipeptide class.
Vesilute In Vitro Research Applications
| Research Area | Model Type | Cellular Mechanism of Interest |
|---|---|---|
| Bladder smooth muscle function | Ex vivo tissue / rat model | Detrusor contractility, calcium signaling modulation |
| Urogenital tissue aging | Cell culture / in vitro | Chromatin remodeling, protein synthesis in aging cells |
| Microcirculation biology | Vascular cell models | Glycogen aggregation inhibition, vessel tone regulation |
| Prostate tissue biology | Preclinical / cell model | Cell proliferation modulation, microvascular signaling |
| Inflammatory pathway research | Monocyte / macrophage cell culture | Immune cell infiltration, pro-inflammatory cytokine modulation |
| Neuromuscular voiding models | Observational | Co-mediator activity at micturition neural junctions |
Sourcing Vesilute for Laboratory Research
Reproducible results in urogenital peptide research depend on verified compound identity and batch-to-batch consistency.
BioLongevity Labs supplies research-grade Vesilute (20mg) as a lyophilized powder, manufactured in a U.S. GMP facility and independently verified by three certified third-party laboratories. Every batch ships with a Certificate of Analysis confirming identity via HPLC and LC-MS, alongside complete analytical documentation.
Batch-specific COA data is available for pre-purchase review at 3cafb1ad-c62c-49a1-9fd2-ffdad190b9ac.express.conves.io/all-coas/. All compounds are supplied for in vitro and laboratory research use only and are not intended for human or animal administration.
Summary
Vesilute peptide research remains in earlier stages compared to more extensively characterized cytomedines, but the mechanistic hypotheses — particularly around chromatin-level gene regulation and smooth muscle calcium signaling — offer well-defined research angles for urogenital tissue biology.
Its structural simplicity and tissue-preferential orientation make it a tractable compound for researchers investigating bladder contractile function, prostatic tissue cell biology, and age-related changes in urogenital physiology at the cellular level.
Scientific Reviewer
This research article has been scientifically reviewed and fact-checked by Dr. Ky H. Le, MD. Dr. Le earned his medical degree from St. George’s University School of Medicine and completed his residency training at Memorial Hermann Southwest Hospital. Board-certified in family medicine with experience in hospital medicine, he brings over two decades of clinical experience to reviewing research content and ensuring scientific accuracy.
About BioLongevity Labs
BioLongevity Labs supplies USA-made research peptides for in vitro laboratory applications. All compounds undergo independent third-party testing to verify purity and composition, with full certificates of analysis available for researchers requiring documentation. Browse our complete peptide catalog to find research-grade peptides for your laboratory needs.
References
- Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Springer Science and Business Media LLC; 2009. https://doi.org/10.1007/s10522-009-9249-8
- Arutjunyan AV, Popovich IG, Kozina LS, Ryzhak GA. Peptide Regulation of Ageing: From Experiment to Practice. Bentham Science Publishers Ltd.; 2025. https://doi.org/10.2174/0118746098346230250116065407
- Anisimov VN, Khavinson VKh, Mikhalski AI, Yashin AI. Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. Elsevier BV; 2001. https://doi.org/10.1016/S0047-6374(00)00184-6
- Avolio F, Martinotti S, Khavinson VKh, Esposito JE, Giambuzzi G, Marino A, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. MDPI AG; 2022. https://doi.org/10.3390/ijms23073607
- Jankovic SM, Jankovic SV, Stojadinovic D, Jakovljevic M, Milovanovic D. Effect of exogenous glutamate and N-Methyl-D-aspartic acid on spontaneous activity of isolated human ureter. Wiley; 2007. https://doi.org/10.1111/j.1442-2042.2007.01834.x
- Kovalev GV, Labetov IA, Shakirova RR, Shkarupa DD. The peptide regulator Vezusten in the management of overactive bladder syndrome: an efficacy evaluation. Rostov State Medical University; 2024. https://doi.org/10.21886/2308-6424-2024-12-4-50-56